| Literature DB >> 34836088 |
Paloma K Barrera-Reyes1,2, Josué Cortés-Fernández de Lara1,2, Laure Poquet3, Karine Redeuil3, Martin Kussmann4, Irma Silva-Zolezzi5, Elizabeth M Tejero1.
Abstract
BACKGROUND: While the bioavailability of cocoa polyphenols, particularly of the monomer (-)-epicatechin, has been investigated after a single-dose intake, the effect of sustained cocoa consumption on the metabolic profile of the structurally related (-)-epicatechin metabolites (SREMs) has not been investigated.Entities:
Keywords: antioxidant capacity; cocoa; epicatechin; epicatechin metabolites; healthy adults; polyphenols; quantification
Mesh:
Substances:
Year: 2021 PMID: 34836088 PMCID: PMC8625154 DOI: 10.3390/nu13113829
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study design. The study design was a double-blinded, randomized, crossover clinical trial for the evaluation of single-dose intake in healthy young adults (n = 10 per group) and followed by a controlled parallel-design for evaluation of sustained consumption consisting of daily doses of 1.3 g of the product for 28 ± 3 days (control n = 9 and cocoa n = 10).
Composition of the high polyphenol-containing cocoa product.
| Compound | Mg/g |
|---|---|
| Total polyphenol | 500 |
| Epicatechin a | 78 |
| Flavan-3-ols b | 200 |
| Flavanols | 100 |
| Theobromine | 50 |
Values are in mg/g of cocoa powder. a Determined by Folin–Ciocalteu as catechin. b Determined as catechin, epicatechin, B1, and B2.
Figure 2CONSORT statement. Participants allocated to Group A consumed the treatment in a cocoa–control sequence and those in Group B used the opposite order. Twenty participants completed the first phase of the study (single-dose), and nineteen completed the second phase (sustained consumption).
Descriptive characteristics of the participants at baseline. Mean (SD).
| Variable | Group A | Group B | |
|---|---|---|---|
| Sex (male) (%) | 4 (36%) | 6 (67%) | |
| Age (years) | 27.4 (4.0) | 26.7 (5.2) | 0.68 |
| BMI (kg/m2) | 23.7 (2.9) | 23.0 (3.1) | 0.65 |
| Physical activity (METs) | 2512 (2449) | 2197 (1203) | 0.42 |
| Glucose (mg/dL) | 90.9 (6.6) | 90.5 (6.5) | 0.88 |
| Cholesterol (mg/dL) | 158.4 (37.6) | 189.8 (37.8) | 0.06 |
| HDL (mg/dL) | 52.2 (13.0) | 47.6 (12.3) | 0.99 |
| LDL (mg/dL) | 90.2 (34.0) | 117.5(34.7) | 0.13 |
| Triglycerides (mg/dL) | 80.2 (27.2) | 120.7 (56.4) | 0.13 |
| Energy intake (kcal) | 1814 (518) | 2103 (807) | 0.29 |
| Fat mass (%) | 23.5 (5.7) | 25.5 (5.7) | 0.27 |
| Lean mass (kg) | 31.2 (9.5) | 33.2 (12.6) | 0.67 |
* t-test for independent samples.
Figure 3Structurally related (-)-epicatechin metabolites (SREMs) in plasma samples. Ten SREMs were quantified in the plasma samples by UHPLC-MS/MS. An analysis of the single dose was conducted at V1 and V2 (n = 20), and the 28 day consumption was analyzed at V3 (n = 10). The data are presented as the mean percentage after consumption.
Figure 4Abundance in the plasma of structurally related (-)-epicatechin (SREMs) metabolites by sex. An analysis of the single dose was conducted at V1 and V2 (n = 20). Catechin (Cat), (+)-3′-O-methyl epicatechin (3′ME), (−)-4′-O-methyl epicatechin (4′ME), epicatechin (EC), (+)-4′-O-methyl catechin, (−)-epicatechin-4′-O-sulfate (E4’S), (−)-epicatechin-3′-O-sulfate (E3´S), (−)-3′-O-methyl epicatechin-4′-sulfate (3′ME4S), (−)-epicatechin-4′-O- glucuronide (E4′G), 3′-O-glucuronide (E3′G), and (+)-catechin-4′-O-glucuronide (C4′G).